Abbvie to focus on smaller deals after Cerevel and ImmunoGen buyout

ImmunoGen

07/12/2023 14:46

Dec 7 (Reuters) - U.S. drugmaker Abbvie  ABBV.N  said on
Thursday it does not expect any transactions similar to its $8.7
billion buyout of Cerevel Therapeutics  CERE.O  in the
foreseeable future and would instead focus on smaller deals to
support its growth.
    Abbvie's deal to buy Cerevel is its second large deal in the
past week, after it agreed to buy cancer drug developer
ImmunoGen  IMGN.O  for $10.1 billion in cash.

 (Reporting by Bhanvi Satija and Khushi Mandowara in Bengaluru;
Editing by Krishna Chandra Eluri)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))